Hims & Hers' (NYSE: HIMS) stock crashed over 30% following news highlighting the end of its relationship with Novo Nordisk ...

Gain 2x leveraged exposure to HIMS with HIMZ, ideal for high-risk traders. Read more on how to navigate recent volatility and ...

Hims & Hers Health, Inc. (NYSE:HIMS) is one of the 14 stocks Jim Cramer recently shared insights on. Discussing the ...

Hims & Hers rebounded by 11.76 percent on Thursday to close at $46.28 apiece amid reaffirmations to continue offering cheaper ...

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.

This growth stock experienced a significant decline in stock price following an announcement with a key partner. *Stock prices used were the afternoon prices of June 23, 2025. The video was published ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

The collaboration, set to begin on 1 July, will see Novo Nordisk team up with the telehealth company to offer Wegovy to ...

A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some ...